SCHEMBL7264255

SCHEMBL7264255

Nc1[c]cn(C(=O)c2ccccc2)c(=O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 4/20 0.41
NPC1 O15118 3/20 0.41
MEN1 O00255 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DYRK1A Q13627 1/20 0.38
MAPT P10636 2/20 0.36
PKM P14618 2/20 0.36
HPGD P15428 3/20 0.36
F2 P00734 1/20 0.36
NOS1 P29475 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
KDM4E B2RXH2 2/20 0.36
ELANE P08246 2/20 0.36
LMNA P02545 1/20 0.36
F12 P00748 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL210468 0.74 RAB9A (0.51) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL5694141 0.73 DYRK1A (0.47) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL3627806 0.71 DCK (0.43) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL5344718 0.71 RAB9A (0.41) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL10348673 0.70 MAPK14 (0.44) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL8303938 0.68 ABCB1 (0.40) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL27622346 0.67 RAB9A (0.37) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL15474750 0.67 RAB9A (0.50) RAB9ATSHRL3MBTL1KMT2ANPC1
SCHEMBL10348640 0.67 RAB9A (0.46) RAB9ATSHRL3MBTL1NPC1SMN1; SMN2
SCHEMBL10335889 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649750-B1 Nucleoside linked to a support through heterocyclic base and amide bond; deblocking/deprotecting; capping/oxidizing; purity; reduced levels of byproducts containing abasic sites ISIS PHARMACEUTICALS, INC. 2003-11-18 US claimed